Chugai Pharmaceutical Co., Ltd. Share Price
Stocks
4519
JP3519400000
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
07:30:00 21/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 7,011.00 JPY | -1.27% |
|
+1.13% | -14.95% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-18 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 11,535B 72.56B 62.15B 58.16B 53.24B 99.91B 6,942B 101B 687B 268B 3,488B 272B 267B | P/E 2026 * |
22.8x | P/E 2027 * | 19.6x |
|---|---|---|---|---|---|
| Enterprise Value | 10,625B 66.83B 57.25B 53.57B 49.03B 92.02B 6,395B 93.24B 633B 247B 3,212B 251B 245B | EV / Sales 2026 * |
7.65x | EV / Sales 2027 * | 6.77x |
| Free-Float |
38.12% | Yield 2026 * |
1.94% | Yield 2027 * | 2.21% |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | -1.27% | ||
| 1 week | +1.13% | ||
| Current month | +1.14% | ||
| 1 month | -5.22% | ||
| 3 months | -10.53% | ||
| 6 months | -29.40% | ||
| Current year | -14.95% |
| 1 week | 6,831 |  | 7,141 |
| 1 month | 6,575 | | 7,509 |
| Current year | 6,575 | | 10,700 |
| 1 year | 6,002 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 28/02/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 27/03/2024 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 29/02/2020 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 27/03/2024 |
| Director/Board Member | 51 | 28/02/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.27% | +1.13% | +11.29% | +65.82% | 72.56B | |
| +0.88% | +6.38% | +76.86% | +128.23% | 1,119B | |
| +1.07% | +3.80% | +51.03% | +61.48% | 651B | |
| +1.20% | +6.21% | +26.47% | +76.45% | 468B | |
| +1.02% | +5.77% | +43.09% | +47.70% | 374B | |
| +0.85% | +4.07% | +23.88% | +41.58% | 302B | |
| +1.26% | +6.81% | +1.59% | +14.67% | 259B | |
| +1.88% | +5.81% | +48.54% | +68.52% | 238B | |
| +1.59% | +2.09% | -15.52% | -52.29% | 208B | |
| +1.87% | +5.61% | +25.81% | +92.42% | 181B | |
| Average | +1.04% | +4.59% | +29.30% | +54.46% | 387.24B | |
| Weighted average by Cap. | +1.09% | +5.02% | +43.69% | +72.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,389B 8.73B 7.48B 7B 6.41B 12.03B 836B 12.19B 82.71B 32.26B 420B 32.8B 32.08B | 1,533B 9.64B 8.26B 7.73B 7.08B 13.28B 923B 13.45B 91.32B 35.61B 464B 36.21B 35.42B |
| Net income | 507B 3.19B 2.73B 2.56B 2.34B 4.39B 305B 4.45B 30.21B 11.78B 153B 11.98B 11.72B | 588B 3.7B 3.17B 2.96B 2.71B 5.09B 354B 5.16B 35.02B 13.66B 178B 13.88B 13.58B |
| Net Debt | -910B -5.73B -4.9B -4.59B -4.2B -7.88B -548B -7.99B -54.21B -21.14B -275B -21.5B -21.03B | -1,152B -7.25B -6.21B -5.81B -5.32B -9.98B -693B -10.11B -68.61B -26.76B -348B -27.21B -26.62B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/08/26 | JP¥7,011.00 | -1.27% | 1,887,500 |
| 20/08/26 | JP¥7,101.00 | +3.14% | 2,536,300 |
| 19/08/26 | JP¥6,885.00 | +0.55% | 3,127,400 |
| 18/08/26 | JP¥6,847.00 | -0.25% | 2,180,500 |
| 17/08/26 | JP¥6,864.00 | -1.00% | 1,900,800 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
